CRONOS研究中局部进展期直肠癌新辅助治疗结束至择期切除术的时间间隔
这项队列研究纳入6家转诊中心2005年1月至2020年12月间完成新辅助治疗并接受全直肠系膜切除术的1506例局部进展期直肠癌患者,按治疗结束至手术间隔分为短(≤8周)、中(>8且≤12周)、长(>12周)三组。中位随访33个月,长间隔组与中间隔组相比病理完全缓解无显著关联,但不良反应和全身复发风险更低,而转开腹风险、轻微术后并发症和直肠系膜不完整风险更高。
要点
- 长间隔(>12周)与中间隔相比,病理完全缓解无显著关联(OR 1.07,95%CI 0.73-1.61)。
- 长间隔组不良反应(TRG 2-3)风险更低(OR 0.47,95%CI 0.24-0.91),全身复发风险更低(HR 0.59,95%CI 0.36-0.96)。
- 长间隔组转开腹风险更高(OR 3.14,95%CI 1.62-6.07),轻微术后并发症风险更高(OR 1.43,95%CI 1.04-1.97),直肠系膜不完整风险更高(OR 1.89,95%CI 1.02-3.50)。
核心结论
- 新辅助治疗结束至手术间隔超过12周与肿瘤退缩分级改善和全身复发风险降低相关,但可能增加手术复杂性和轻微并发症。
研究设计与样本
- 这项队列研究纳入6家转诊中心2005年1月至2020年12月间完成新辅助治疗并接受全直肠系膜切除术的1506例局部进展期直肠癌患者。
- 按新辅助治疗结束至手术间隔分为短(≤8周,511例,33.9%)、中(>8且≤12周,797例,52.9%)、长(>12周,198例,13.1%)三组,采用逆概率治疗加权法均衡组间,中位随访33个月。
主要发现
- 总体病理完全缓解率为17.2%(259/1506,95%CI 15.4%-19.2%)。
- 与中间隔组相比,短间隔组病理完全缓解无显著关联(OR 0.74,95%CI 0.55-1.01),长间隔组也无显著关联(OR 1.07,95%CI 0.73-1.61)。
- 与中间隔组相比,长间隔组不良反应(TRG 2-3)风险更低(OR 0.47,95%CI 0.24-0.91),全身复发风险更低(HR 0.59,95%CI 0.36-0.96)。
- 与中间隔组相比,长间隔组转开腹风险更高(OR 3.14,95%CI 1.62-6.07),轻微术后并发症风险更高(OR 1.43,95%CI 1.04-1.97),直肠系膜不完整风险更高(OR 1.89,95%CI 1.02-3.50)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The treatment for extraperitoneal locally advanced rectal cancer (LARC) is neoadjuvant therapy (NAT) followed by total mesorectal excision (TME). Robust evidence on the optimal time interval between NAT completion and surgery is lacking. OBJECTIVE: To assess the association of time interval between NAT completion and TME with short- and long-term outcomes. It was hypothesized that longer intervals increase the pathologic complete response (pCR) rate without increasing perioperative morbidity. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with LARC from 6 referral centers who completed NAT and underwent TME between January 2005 and December 2020. The cohort was divided into 3 groups depending on the time interval between NAT completion and surgery: short (≤8 weeks), intermediate (>8 and ≤12 weeks), and long (>12 weeks). The median follow-up duration was 33 months. Data analyses were conducted from May 1, 2021, to May 31, 2022. The inverse probability of treatment weighting method was used to homogenize the analysis groups. EXPOSURE: Long-course chemoradiotherapy or short-course radiotherapy with delayed surgery. MAIN OUTCOME AND MEASURES: The primary outcome was pCR. Other histopathologic results, perioperative events, and survival outcomes constituted the secondary outcomes. RESULTS: Among the 1506 patients, 908 were male (60.3%), and the median (IQR) age was 68.8 (59.4-76.5) years. The short-, intermediate-, and long-interval groups included 511 patients (33.9%), 797 patients (52.9%), and 198 patients (13.1%), respectively. The overall pCR was 17.2% (259 of 1506 patients; 95% CI, 15.4%-19.2%). When compared with the intermediate-interval group, no association was observed between time intervals and pCR in short-interval (odds ratio [OR], 0.74; 95% CI, 0.55-1.01) and long-interval (OR, 1.07; 95% CI, 0.73-1.61) groups. The long-interval group was significantly associated with lower risk of bad response (tumor regression grade [TRG] 2-3; OR, 0.47; 95% CI, 0.24-0.91), systemic recurrence (hazard ratio, 0.59; 95% CI, 0.36-0.96), higher conversion risk (OR, 3.14; 95% CI, 1.62-6.07), minor postoperative complications (OR, 1.43; 95% CI, 1.04-1.97), and incomplete mesorectum (OR, 1.89; 95% CI, 1.02-3.50) when compared with the intermediate-interval group. CONCLUSIONS AND RELEVANCE: Time intervals longer than 12 weeks were associated with improved TRG and systemic recurrence but may increase surgical complexity and minor morbidity.
引用
- Guzmán Y, Ríos J, Paredes J, et al. Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study. JAMA Surg. 2023. PMID: 37436726. doi:10.1001/jamasurg.2023.2521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。